Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4588 - Exploratory study of CK-M30 and pHH3 expression in Circulating Tumor Cells (CTCs) as biomarkers of docetaxel (DOC) efficacy in metastatic castration resistant prostate cancer (mCRPC)


11 Sep 2017


Poster display session


Paz Nombela Blanco


Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390


P. Nombela Blanco1, R. Lozano Mejorada1, D. Lorente Estelles2, A. Reid3, N. Romero Laorden1, G. Attard3, Y. Cendón Flórez4, J. Mateo5, S. Sandhu6, C. Massard7, A. Montesa8, P. Flohr3, M.I. Sáez9, M.I. Pacheco4, E. Castro Marcos1, J. de Bono10, D. Olmos Hidalgo11

Author affiliations

  • 1 Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, 28029 - Madrid/ES
  • 2 Medical Oncology, Hospital Universitari i Politècnic La Fe, Valencia/ES
  • 3 Oncology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB
  • 4 Prostate Cancer Unit, CNIO- Spanish National Cancer Center, 28029 - Madrid/ES
  • 5 Drug Development Unit, The Institute of Cancer Research & Royal Marsden  , Sutton/GB
  • 6 Department, Peter MacCallum Cancer Center, 3002 - Melbourne/AU
  • 7 Early Drug Development Department, Institut de Gustave Roussy, Villejuif/FR
  • 8 Cnio-ibima Genitourinary Research Unit, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga/ES
  • 9 Medical Oncology, H Universitario Virgen de la Victoria y Regional de Málaga, Malaga/ES
  • 10 Section Of Medicine, Institute of Cancer Research Royal Marsden Hospital, SM2 5PT - Sutton/GB
  • 11 Prostate Cancer Clinical Cancer Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid/ES


Abstract 4588


A drop in CTCs counts as early as 4 weeks following treatment initiation have been suggested as an indicator of overall survival (OS) benefit. DOC remains a pivotal treatment in mCRPC for which there are no early pharmacodynamic (PD) markers of its activity in patients (pts). CTCs may be used as surrogate tumor tissue to study PD markers of apoptosis (CK-M30) or mitosis arrest (pHH3) in mCRPC pts receiving DOC.


We conducted a prospective 2-cohort multicenter exploratory study in mCRPC pts progressing by PCWG2 criteria who were eligible for DOC 75 mg/mˆ2. Pts were prescreened using the CellSearch system and selected if CTCs≥5/7.5mLs of blood (Basal 1). A 2nd blood sample (Basal 2) was drawn in eligible pts within 0-7 days prior to C1D1 of DOC and further samples were collected at 8h, 24h, 7d and 21d. Directly conjugated mAb against pHH3 and CK-M30 were used in combination with CellSearch. Statistical analyses were performed to evaluate the baseline and post-treatment variability. Increases in % of biomarker CTC+ greater than the median baseline variability were correlated with achieving a 50% PSA response (PSA50) and OS from DOC start using chi-square and long-rank test, respectively.


60 mCRPC pts (CK-M30 = 30; pHH3 = 30), 95% ECOG 0-1, 95% and 17% have bone and visceral metastases respectively, received a median of 7 cycles (range 2-10) of DOC. Biomarker results are summarised in Table.Table:

1674P Variability

Basal 1 (N = 60) Median (Range)Basal 2 (N = 57) Median (Range)%marker Corr. CoeffPost-24h (n = 59) median (Range)P-value Basal vs post-24h
Cohort CK-M30CTC/7.5mL9 (5-1266)8 (3-863)0.54 p = 0.7639 (4-1129)NS
CK-M30+48% (0-76%)35% (0-100%)51% (0-100%)
Cohort pHH3CTC/7.5mL10 (5-567)12 (4-623)0.98 p 


pHH3 in CTC+ may be a potential PD biomarker of a favourable response to DOC treatment.

Clinical trial identification

Legal entity responsible for the study

Spanish National Cancer Research Centre




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.